Trial Profile
Single-ascending dose study of ABT 267 in volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Apr 2011
Price :
$35
*
At a glance
- Drugs Ombitasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories
- 01 Apr 2011 New trial record